Table 1.
Baseline characteristics and demographics of the SOLACE-adults study population
| Crizanlizumab, 5.0 mg/kg, N = 45 | Crizanlizumab, 7.5 mg/kg, N = 12 | |
|---|---|---|
| Age, y | ||
| Mean (SD) | 32 (12.7) | 27 (12.3) |
| Median (range) | 29 (17-65) | 21 (16-48) |
| Sex, n (%) | ||
| Female | 25 (55.6) | 6 (50.0) |
| Male | 20 (44.4) | 6 (50.0) |
| Race, n (%) | ||
| Black or African American | 44 (97.8) | 12 (100) |
| White and Black or African American∗ | 1 (2.2) | 0 |
| Ethnicity, n (%) | ||
| Not Hispanic or Latino | 33 (73.3) | 8 (66.7) |
| Hispanic or Latino | 3 (6.7) | 0 |
| Unknown | 9 (20.0) | 4 (33.3) |
| Genotype, n (%) | ||
| HbSS | 27 (60.0) | 4 (33.3) |
| HbSC | 10 (22.2) | 5 (41.7) |
| HbSβ0 thalassemia | 3 (6.7) | 0 |
| HbSβ+ thalassemia | 3 (6.7) | 0 |
| Other/unknown | 2 (4.4) | 3 (25.0) |
| Concomitant HU/hydroxycarbamide, n (%) | ||
| Yes | 33 (73.3) | 7 (58.3) |
| No | 12 (26.7) | 5 (41.7) |
| Patients’ VOCs in prior 12 mo, n (%) | ||
| <5 | 26 (57.8) | 9 (75.0) |
| ≥5 | 19 (42.2) | 3 (25.0) |
| Patients’ VOC type in prior 12 mo, n (%) | ||
| Uncomplicated sickle cell VOC | 44 (97.8) | 11 (91.7) |
| Acute chest syndrome | 4 (8.9) | 2 (16.7) |
| Priapism | 2 (4.4) | 0 |
HbSS, hemoglobin SS; SD, standard deviation.
∗
Patients of mixed descent.